Shivananda S, BDS, MDS

home / authors / shivananda-s-bds-mds

Articles

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Vidya G Doddawad, BDS, MDS;B.M. Gurupadayya;Vidya CS;Shivananda S, BDS, MDS;Karthikeya Patil;R. Sumukh Bharadwaj
April 16th 2025

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.

Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report

Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report

Sahith Kumar Shetty, BDS, MDS;Vidya G Doddawad, BDS, MDS;Shyam Sundar S, BDS, MDS;Shivananda S, BDS, MDS
November 14th 2023

A case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Liver Mass Found in 38-Year-Old Woman
Published: January 28th 2017 | Updated: April 25th 2025
Liver Mass Found in 38-Year-Old Woman